Recurrent and clonal genetic alterations in different subtypes of Acute Lymphoblastic Leukemia (ALL) are well-characterised, and associated with differences in disease outcome. MRC Holland's SALSA^® MLPA^® technology has become a prime method in studying CNAs in ALL, especially IKZF1^del. D007 Acute Lymphoblastic Leukemia is based on the groundbreaking SALSA^® digitalMLPA™ technology, which combines the broad scale of next generation sequencing with the unparalleled sensitivity in CNA detection of MLPA.